News
Summit Therapeutics nears a $15B AstraZeneca deal for ivonescimab, targeting a $90B market. See more on the potential and ...
It might be gearing up to pay billions of dollars to participate in a drug program currently in development. AstraZeneca ...
UK pharma major AstraZeneca is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal ...
The Manila Times on MSN4h
AstraZeneca eyes licensing lung cancer drugASTRAZENECA is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal worth as much as $15 billion, Bloomberg News reported on Thursday, citing people familiar with ...
Stocks fade as tariff deadline looms large - US President Donald Trump said he plans to start sending letters informing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback